Table 1 MF tumor samples subjected to... | American Society of Hematology

Table 1

MF tumor samples subjected to WGS

Patient	Ethnicity	Sex	Age, y	Tumor site	Normal tissue site	Pathology	Past therapy	Current therapy	TNMB	Clinical stage
1	White	Female	70	Knee	Back	Nontransformed	XRT	Bexarotene, vorinostat	T3, N0, M0, B0	IIB
2	White	Male	67	Upper arm	Abdomen	Granulomatous	NB-UVB	Bexarotene	T3, N2, M0, B0	IIB
3	White	Male	41	Forearm	Abdomen	Nontransformed	Bexarotene	NB-UVB, topical bexarotene	T3, N0, M0, B0	IIB
4	Black	Male	35	Scalp	Forearm	Large cell transformed	XRT, ECP bexarotene, romidepsin	Gemcitabine	T3, N2, M0, B2	IVA₁
5	White	Female	69	Upper arm	Abdomen	Nontransformed	None	None	T3, N0, M0, B0	IIB

Patient	Ethnicity	Sex	Age, y	Tumor site	Normal tissue site	Pathology	Past therapy	Current therapy	TNMB	Clinical stage
1	White	Female	70	Knee	Back	Nontransformed	XRT	Bexarotene, vorinostat	T3, N0, M0, B0	IIB
2	White	Male	67	Upper arm	Abdomen	Granulomatous	NB-UVB	Bexarotene	T3, N2, M0, B0	IIB
3	White	Male	41	Forearm	Abdomen	Nontransformed	Bexarotene	NB-UVB, topical bexarotene	T3, N0, M0, B0	IIB
4	Black	Male	35	Scalp	Forearm	Large cell transformed	XRT, ECP bexarotene, romidepsin	Gemcitabine	T3, N2, M0, B2	IVA₁
5	White	Female	69	Upper arm	Abdomen	Nontransformed	None	None	T3, N0, M0, B0	IIB

ECP, extracorporeal photopheresis; NB-UVB, narrow-band UV B; TNMB, tumor, node, metastasis, blood; XRT, local radiation therapy.